The OLR1/NF-κB feedback loop exacerbates HIV-1 Tat-induced microglial inflammatory response and neuronal apoptosis

Journal of NeuroVirology, Journal Year: 2025, Volume and Issue: unknown

Published: March 26, 2025

Language: Английский

---

Development of viral infectious clones and their applications based on yeast and bacterial artificial chromosome platforms

Molecular Biomedicine, Journal Year: 2025, Volume and Issue: 6(1)

Published: April 29, 2025

Abstract Infectious Clones represent a foundational technique in the field of reverse genetics, allowing for construction and manipulation full-length viral genomes. The main methods currently used constructing infectious clones include Transformation-associated recombination (TAR), which is based on Yeast Artificial Chromosome (YAC) Bacterial (BAC). YAC BAC systems are powerful tools that enable large DNA fragments, making them well-suited These have been successfully applied to construct wide range viruses, including coronaviruses, herpesviruses, flaviviruses baculoviruses. rescued recombinant viruses from these widely various research areas, such as vaccine development, antiviral drug screening, pathogenesis virulence studies, gene therapy vector design. However, different possess unique biological characteristics, challenge remains how rapidly obtain future research. In summary, this review introduced development applications clones, with focus YAC, combined YAC-BAC technologies. We emphasize importance platforms areas aim provide deeper insights can advance platform broaden its application horizons.

Language: Английский

---

The miRNomics of antiretroviral therapy-induced obesity

Functional & Integrative Genomics, Journal Year: 2025, Volume and Issue: 25(1)

Published: April 5, 2025

Language: Английский

---

Current and Emerging Therapeutic Strategies for Chronic Hepatitis B Virus Infection: A Review

European Journal of Medical and Health Sciences, Journal Year: 2025, Volume and Issue: 7(3), P. 1 - 9

Published: May 1, 2025

The main objective in treating chronic hepatitis B (CHB) is to achieve sustained suppression of HBV DNA order slow or prevent the progression liver disease. Interferon-alpha nucleoside analog therapy aims reduce levels below 105 copies/mL HBeAg-positive cases, and even lower HBeAg-negative cases. HBeAg seroconversion HBsAg loss are important markers treatment success, though remains infrequent. Interferon-based therapies have shown higher rates compared analogs, which likely due their differing mechanisms action. Treatment selection based on patient-specific factors, including baseline ALT levels, histology, patient’s ability tolerate side effects. Global guidelines recommend initiating for patients with elevated greater than 20,000 IU/mL, along ongoing monitoring resistance adherence. Recent advancements antiviral agents, such as tenofovir entecavir, improved efficacy reduced older treatments like lamivudine. Special considerations necessary populations pregnant women, individuals cirrhosis, those co-infected HIV HCV. While combination may offer potential benefits, optimal use still requires further research. Long-term essential achieving durable responses improving outcomes management CHB.

Language: Английский

---

Roles of Macrophages in Viral Infections

Viruses, Journal Year: 2024, Volume and Issue: 16(10), P. 1643 - 1643

Published: Oct. 21, 2024

Macrophages are an important component of the first-line defense against pathogens, including viruses [...].

Language: Английский

---